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S_y Epidemiological and experimental evidnc indicates that oestrogens are involved in the carcino-
genic promotion of human breast cancer. We have undertaken a pilot trial of tamoxifen, an anti-oestrogen,
compared to placebo given to 200 women at a high risk of developmg breast cancer. The results of this trial
show that acute toxicity is low and that accrual and comphance are satisfactory. Furthermore, biochemcal
monitorng of lipids and dotting factors indicate that tamoxifen may reduce the nsk of cardiovascular deaths.
At this stage no untoward long-term risks have been identified and it is therefore proposed that a large
multicentre trial should be started.
Experimental evidence indicates that oestrogens are involved
in carcinogenic promotion of mouse mammary tumours
(Jordan et al., 1980; Jordan 1981). In humans epidemio-
logical evidence supports the hypothesis that this mechanism
may be important in the promotion of breast cancer (Miller
& Bulbrook, 1980). This raises the therapeutic possibility
that endocrine intervention could prevent breast cancer,
(Cusick et al., 1986) but it seems unlikely that more
extensive epidemiological studies will adequately test this
hypothesis.
An alternative approach would be to undertake a clinical
trial using an effective anti-oestrogenic intervention in high
risk women. This would not only provide evidence as to
whether anti-oestrogenic intervention could prevent breast
cancer, but also give strong indications about mechanisms of
carcinogenesis in human breast cancer.
The epidemiological studies of breast cancer incidence
following the atomic bomb explosions in Japan in 1945
indicate that ovarian function is required for endocrine
promotion of radiation induced breast cancers. The incidence
of breast cancer did not start to increase until about 13 years
after radiation (Tokunaga et al., 1979) and continues to
increase 30 years later (Tokunaga et al., 1984). This would
suggest that endocrine prevention trials would require long
periods of follow-up before any beneficial effects could be
detected.
The number of women required for a prevention trial will
depend on the number of cancers which eventually develop
in the trial population. This, in turn, is a function of the
relative risk of women chosen, the duration of follow-up and
the magnitude of the preventative effect. In order to detect a
75% reduction only 15 breast cancers need to develop in the
test population, whereas 300 cancers would be required in
order to detect a 25% reduction. For unselected women in
the UK aged between 35 and 65, the risk of breast cancer is
approximately 1.75 per 1,000 per year (Cancer Statistics,
1984) whereas women aged 50-60 with a first degree female
family history of breast cancer have a risk of 5-6 per 1,000
per year. Of these high risk women, 5,000 will develop 250-
300 cancers over a 10-year follow-up period.
Thus, in order to have a reasonable chance of detecting
significant prevention by anti-oestrogenic intervention,
approximately 5,000 high-risk women would be required,
with a 10-20 year follow-up. Were compliance maintained at
only 50%, four times this number of women would be
needed. This requires that the anti-oestrogenic intervention
be well tolerated and easy to administer and maintain.
There are various anti-oestrogenic options available. A
low fat diet may reduce oestrogenic activity (Rose et al.,
1987) but strict dietary control is required and it is unlikely
that this could be maintained for the time required for
adequate protection. Non-randomised studies indicate that
oophorectomy or ovarian irradiation will substantially
reduce the incidence of breast cancer, the degree of protec-
tion being related to age at ablation (MacMahon & Feinlieb,
1960; Hirayama & Wynder, 1962). However, it is neither
realistic nor ethical to propose a 5,000 women ovarian
ablation trial. An attractive alternative is the use of a
physiological antagonist of oestrogen, such as a progestin or
androgen, perhaps in combination with oestrogen as an oral
contraceptive or as hormone replacement therapy. However,
there is doubt as to whether a progestin would protect
against breast cancer (Key & Pike, 1988).
Tamoxifen, a relatively seective anti-oestrogen, is effective
treatment for endocrine sensitive breast cancer with virtually
no side-effects (Cole et al., Ward, 1973). When given to
women with primary breast cancer it delays relapse and
prolongs survival (Scottish Breast Cancer Trials Report,
1987; Nato Report, 1980; CRC Report, 1988). It is also an
effective treatment for primary breast cancer in some elderly
patients (Bradbeer & Kyngdon, 1983). Tamoxifen has been
used to treat breast cancer since 1969 and no untoward long-
term side effects have been identified in humans. Further-
more, preliminary toxicity studies indicate that tamoxifen is
not anti-oestrogenic on other important tissues in the body,
such as bone (Fentiman et al., 1988), where lack of oestro-
gen could promote osteoporosis. Mutagenicity studies have
indicated that, like oestrogen, tamoxifen at high dosages can
cause bepatocellular cancer in the rat (DeWaard & Wang,
1988). Tamoxifen is generally oestrogenic in the rat and this
effect is similar to that seen with the oral contraceptive pill.
Hepatocellular cancer has not been reported in women
taking tamoxifen and it appears likely that this risk is very
small (Fentiman & Powles, 1987). With regard to other
tumours,.experimental evidence indicates that tamoxifen may
be oestrogenic on the endometrium (Gottardis & Robinson,
1988) with a potential associated risk of causing endometrial
cancer (Hardell, 1988; Jordan, 1988).
Retrospective analysis of new primary cancers in women
on adjuvant tamoxifen (40 mg day-) in Sweden indicate an
increased risk of endometrial cancer (Fornander et al., 1989),
although this has not been confirmed in the Scottish trial
giving adjuvant tamoxifen 20 mg day- for 5 years (Steward
& Knight, 1989). This may be related to the higher dosage of
tamoxifen in the Swedish trial. Overall it seems that the ease
of administration, low acute toxicity with prospects of high
long-term compliance, and proven anti-growth properties on
endocrine sensitive breast cancer makes tamoxifen an ideal
agent for a clinical trial of endocrine prevention of breast
cancer.
We have therefore started a pilot double blind clinical trial
of tamoxifen versus placebo in women with a high risk of
developing breast cancer, in order to assess the feasibility of
a large prevention programme.
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Trial design
This double blind, placebo-controlled feasibility trial was
designed to accrue 200 well women with at least one first
degree relative who had had breast cancer. The initial draft
protocol was drawn up in July 1985 and the proposed plan
was presented to hospital colleagues, local general practi-
tioners, potential participating women, the Cancer .Resrch
Campaign and the British Breast Group. In October 1986,
ethical clearance was granted by the Royal Marsden
Hospital, requiring informed, written and witnessed consent.
Women were prescribed 'tamoplac' 20 mg day-' and were
randomised to receive tamoxifen 20 mg day-' or placebo.
Between October 1986 and June 1987, 124 women were
randomised. Accrual was then stopped following a muta-
genicity report by ICI of liver tumours occurring in rats
given high oral doses of tamoxifen. After further consider-
ation by our Ethics Committee, ethical clearance was re-
confirmed. Accrual was recommenced in February 1988,
with stricter eligibility criteria (age and family history) and
more extensive informed consent. The total of 200 patients
for this feasibility trial was reached by October 1988.
Now that recruitment to this tnral is complete, this interim
analysis reports our rate of accrual, compliance, toxicity and
monitoring for the first 2 years in order to assess if there is
sufficient information to justify a large multicentre trial.
Participants and methods
All women attending a symptomatic Medical Breast Clinic
(SBC) at the Royal Marsden Hospital, Sutton or a screening
clinic in the Early Diagnostic Unit (EDU) at the Royal
Marsden Hospital, Fulham Road, aged 36-65 years old, who
were neither pregnant nor at risk of pregnancy, not taking
oral contraceptives or hormone replacement therapy, and
who had no clinical or radiological evidence of breast cancer,
were considered eligible for this trial. All eligible women
were required to have at least one, and after February 1988
two, first degree female relatives with breast cancer. They
were required to be psychologically, physically and geo-
graphically suitable for long-term screening. After counsel-
ling, eligible women were offered participation in the trial.
including regular screening and monitoring. For entry,
informed, witnessed and written consent was required.
At the commencement of the trial, the women were
clinically assessed for breast abnormalities, with mammo-
graphy, breast ultrasound and needle aspiration cytology
where indicated. Post-randomisation, the women were seen
at 3 and 6 months and then every 6 months for clinical
examination, assessment of compliance and acute toxicity.
During the development of this feasibility trial further
monitoring was incorporated into the protocol as detailed
below.
When possible serum oestradiol (E2) and sex hormone
binding globulin (SHBG) were measured pre-treatment and
at 3, 6, 9, 12, 18 and 24 months, in peri, post-menopausal
and post-hysterectomy women. Pre-menopausal women had
luteal and follicular-phase bloods taken pre-treatment and
repeated at the above intervals. Serum was stored for other
hormone measurements at a later stage.
The clotting factors anti-thrombin 3 and fibrinogen were
measured if possible every 6 months along with a fasting
lipid profile of total cholesterol, HDL cholesterol and tnrgly-
ceride.
Some women in this study reported lower abdominal pains
possibly caused by the development of ovarian cysts. We
therefore undertook sequential pelvic ultrasound on a sub-
section of women using an Acuson scanner.
The risk of causing or aggravating osteoporosis by anti-
oestrogenic intervention indicated a need for sequential
measurement of bone mass. Hormone dependent bone mass
can be adequately monitored by single photon absorption
through the forearm using a bone densitometer (ND 110
Nuclear Data Inc.) (Christiansan & Rodbro, 1977;
Christiansan et al., 1981). This was repeated at 6-monthly
intervals for the first 2 years and will be continued annually.
It is planned to continue medication, monitoring and
screening in these 200 women for as long as is acceptable in
order to gain information regarding long-term compliance
and toxicity.
Results
Until the stricter consent cnteria were instituted in February
1988, 76 eligible women with at least one first degree relative
with breast cancer consented to enter the trial from the EDU
compared to 50 women for the SBC. From February 1988 to
October 1988, 61 women from the EDU consented com-
pared to 13 from the SBC (Table I).
After the change in eligibility criteria and consent in
February 1988, a subpopulation of 242 women attending the
EDU with a family history of breast cancer were assessed for
reasons of non-eligibility and non-consent (Table II).
Although an average of 11.5 women with a family history of
breast cancer attended the clinic only an average of 2.7 were
eligible, 47% of whom consented to inclusion after informed
consent. Details of the reasons for ineligibility and non-
consent are given in Table II.
For all 200 women randomised the age, menopausal status
and extent of family history were similar for the tamoxifen
and placebo women (Table III). Compliance to medication
for the first year, as assessed by interview, was high and the
same for both groups. This reflects the relatively low toxicity
for tamoxifen versus placebo (Table IV). Apart from hot
flushes which occurred in 27% of tamoxifen women versus
11% of placebo women (P<0.005) there was no significant
differences between the two types of medication.
Non-compliance related to toxicity was similar for both
groups of women, with seven tamoxifen and six placebo
women temporarily stopping medication. Permanent ces-
sation of medication occurred in 18 tamoxifen versus 12
placebo women (n.s.) (Table V).
Table I Overall accrual rate of women for the Early Diagnostic
Unit (EDU) and the Symptomatic Breast Clinic (SBC)
EDU SBC Total
Oct. to Dec. 1986 5 16 21
Jan. to Mar. 1987 28 17 45
Apr. to June 1987 42 16 58
July to Sep. 1987 1 0 1
Oct. to Dec. 1987 0 1 1
Jan. to Mar. 1988 10 4 14
Apr. to June 1988 13 5 18
July to Sep. 1988 38 4 42
Table H Eligibility, consent and accrual rates into the tamoxifen
prevention trial for the sample population attending 21 screening
sessions in the EDU between February and July 1988
No. of women with FH 242 11.5/clinic
No. eligible 62 (26%) 2.95/clinic
Ineligible 180
Age 40-60 years 65 (36%)
Pregnancy risk 89 (49%)
Family history <1 relative 75 (42%)
Pill or HRT 22 (12%)
General medical 20 (11%)
Carcinoma on screen 1 (0.4%)
No. consenting (% of eligible) 29 (47%) 1.4/clinic
Non-consent 33
Geographical 10
Not acceptable 24
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Table I Characteristics of 100 women randomised to tamoxifen
compared to 100 women randomised to placebo
Tamoxifen Placebo
(100) (100)
Age, mean years (range) 48 (31-66) 49(30-64)
Family history of 1st degree
relative
0 2 0 n.s.
1 38 47
2 35 36
>2 24 14
Premenopausal 58 52 n.s.
Perimenopausal
(<2 yearsLMP) 2 1
Post-menopausal 23 24
Post-hysterectomy 15 21
Compliance
3 months 89% 94% n.s.
6 months 85% 91%
9 months 83% 88%
12 months 83% 85%
Tabl IV Number (%) of women with acute toxicity, symptomatic
effects and compliance for 75 women on tamoxifen compared to 75
women on placebo, who had been on medication for at kast 3
months
Tamoxifen Placebo
No. (%) No. (%)
Side-effects
Nausea/sickness 6 (8) 11 (15) n.s.
Headaches 7 (9) 5 (7) n.s.
Hot flushes 20 (27) 8 (11) P<0.005
Amenorrhoea 10 (13) 9 (12)
Vaginal discharge 4 (5) 0
Weight gain (>2kg) 3 (4) 3
Muscle cramps 4 (5) 0
Depression I (1) 0
Abdominal pains 2 (3) 0
Symptomatic relief
Breast pain 8/13 10/21
Breast nodules 22/52 17150
Premenstrual
Breast symptoms 18/24 17/24
Fluid retention 9/19 6/18
Headaches 8/13 4/13
Tension 7/12 2/8
Ovarian ultrasound was carried out in 19 women before
the start of medication and 38 women up to one year later
(Table VI). Five (25%) of the 20 women on tamoxifen had
at least one ovarian cyst identified compared to two of 19
pre-treatment and none of 18 post-placebo women (i.e. a
total of two cysts (4%) in 37 non-tamoxifen women).
Sequential pelvic ultrasound studies continue on as many
women as possible in order to assess the clinical significance
of these findings.
Clotting studies were undertaken in as many women as
possible at various times during the trial, measuring levels of
fibrinogen and anti-thrombin 3 (Figure 1). There was a non-
significant trend towards lower levels of fibrinogen, and, to a
lesser extent, anti-thrombin 3 for women on tamoxifen.
Table VI Ovaran ultrasound (Acuson Scanner) on 55 women, 19
pre-medication, 20 post-medication on tamoxifen and 18 post-
medication on placebo (two women had sequential studies)
Pre-treatment Post-treatment
(19) (38)
Tamoxifen 10 20
Normal 7 11
Cyst 1 5 (25%) n.s.
Fibroids 2 4
Placebo 9 18
Normal 8 16
Cysts 1 0
Fibroids 1 2
Tam 14 8 14 6 8 7
Plac 10 9 18 9 13 3
300 -
E
200 -
30 -
Table V Non-compliance of tamoxifen/placebo medication
Tamoxifen Placebo
Temporarv cessation
Non-toxic
Toxic
Nausea
Headaches
Hot flushes
Weight gain
Irregular periods
Vaginal discharge
Other
Permanent cessation
Non-toxic
Toxic
Nausea
Vomiting
Headaches
Hot flushes
Weight gain
Irregular periods
Abdominal pain
Vaginal discharge
Other
8
7
l
°1 0
0
1 18
12
3
14 1
1
1
4
'Including two non-starters.
7
6
1
2
1
2
0
0
0
12
6
6
2
1
1
1
0
2
0
0
3
25 -
n.s.
20 -
1 5-
co
cr- n.s.
n-&
1 0-
Fibrinogen
W Tl 0
AT3
Fibrinogen AT3
I I I I I
0 3 6 9 12 15
Months
Fgwe I Plasma levels of fibrinogen. anti-thrombin 3 (AT3)
and ratio of fibrinogen,AT3 in women receiving tamoxifen
(Tam. * -* or placebo (Plac, Q-O). The number of
women from whom measurements were made at various times
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There was also a trend for a lower fibrinogen/anti-thrombin
3 ratio, which would possibly favour protection against
pathological thrombosis. Most women in the trial are now
included in these studies.
For logistic reasons it was initially difficult to organise a
system for measurement of fasting lipids. However, this is
now underway and women have fasting blood samples taken
whenever possible before commencement of medication.
Although the information to date shows no differences in
tnglycerides, HDL cholesterol or uric acid, levels of total
cholesterol are significantly lower for women on tamoxifen
(Figure 2). Our normal total cholesterol ranges from 3.6 to
6.8 mmol I-1. For sequential measurements in 49 women
the mean change in plasma cholesterol levels on placebo was
-0.08 mmol 1-1 (95% confidence limits +0.27 to -0.42)
compared to -0.85 mmol 1-1 (95% confidence limits -0.45
to - 1.25) (P=0.02) for those on tamoxifen.
Measurement of bone mineral content showed no evidence
of increased bone mineral loss for women on tamoxifen
(Figure 3). Furthermore, tamoxifen had no effect on bone
mineral loss in pre-menopausal compared to post-
menopausal women.
We have undertaken preliminary measurements of serum
E2 and SHBG in some women. There was no difference in
pre-treatment and post-treatment SHBG levels in 20 women
who received placebo (mean -2.6 nmol 1-1, 95% CI, +5
nmol 1- I to -10 nmol I -1) compared to a significant
increase for women on tamoxifen (mean + 14 nmol I 1, 95%
CI, +21 nmol I1 to +8 nmol 11, P<0.001).
Tam33 13 18 6 8 7
Plac 39 13 21 10 18 5
8-
7 -
05 6 -
E
E
5-
4- I I I I
0 3 6 9
Months
Figure 2 The plasma levels of total choleste
receiving tamoxifen (Tam, *0*) or placebo (1
The number of women for whom measurement
various times after randomisation are shown.
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T
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I
Fgue 4 Mean differences between pre- and on-treatment levels
with 95% confidence intervals for tamoxifen (S* *) and
placebo (CO- ) in pre-menopausal (luteal) and post-
menopausal oestradiol (E2) and sex hormone binding globulin
SHBG.
There was no difference in pre- and on-treatment levels of
serum oestradiol for 14 post-menopausal women on placebo
(mean -8 pmol 1-1 95% CI +7 pmol 1-1 to -23 pmol
I-1) or tamoxifen (mean +5 pmol 1-1 95% CI, +50 pmol
I1- to -40 pmol I-1). In contrast there was a significant
increase in on-treatment levels of serum oestradiol for 16 pr-eopua wome who reeie eihe taoie (me[. _._,, an
pre-menopausal women who received either tamoxifen (mean 12 15 +700 pmol 1-1, 95% CI, +1040 pmol 1-1 to +360,
P<0.001) or placebo (mean +262 pmol 1-1, 95% CI +648
rol in women pmol 1-1 to +55 pmol 1-1, P<0.005).
Plac, QO). These results confirm previous reports that tamoxifen
t was made at causes a rise in the serum levels of E2 in pre-menopausal
women (Jordan, 1986) and SHBG in pre- and post-
menopausal women (Sakai et al., 1978). Further analyses of
sequential changes in other hormones are underway.
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Fige 3 Age corrected bone mineral cont
estimated normal measurement using a sin,
bone densitometer. Tamoxifen (Tam.*
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The aim of this trial was to test the feasibility of a large
multicentre prevention trial using tamoxifen in high risk
women. From two breast clinics we were able to identify
about seven eligible women per week and after full discus-
sion approximately 50% of them consented to randomisation
into the trial, in spite of extensive consent and ethical
requirements for this trial. More eligible women were identi-
fied and there was a higher acceptance rate in the screening
clinic, compared to the symptomatic breast clinic. This
12 15 18 presumably reflects an increased interest in early diagnosis
and prevention in this clinic.
ent shown as % of Generally, there was little difference in acute toxicity
gle photon forearm between tamoxifen and- placebo. Hot flushes occurred in
*) or placebo (Plac, significantly more women on tamoxifen but generally were
only mild. Menstrual changes including amenorrhoea were not
Tam 27
Plac 28
130 7
19 18
15 19
--d
-4
I
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symptomatically a problem and relief of pre-menstrual ten-
sion and headaches were of benefit to some patients on
tamoxifen. Cessation of treatment because of toxicity was
similar for tamoxifen and placebo. Compliance was the same
for tamoxifen and placebo and was surprisingly high, with
greater than 80% of women continuing medication after the
first year. This relates to the ease of medication and low
toxicity and may approach the maximum achievable com-
pliance with any endocrine intervention.
With regard to long-term toxicity we are, at present
unable to identify any changes which might indicate future
potential risks. Changes in lipids and SHBG indicate a
similar oestrogenic effect on the liver to those reported with
oral contraceptives or hormone replacement therapy (Sakai
et al., 1978; Rossner & Wallgren, 1984). The effects that
these changes may have on the incidence of coronary heart
disease or atherosclerosis are difficult to predict. It would
seem that a rise in HDL cholesterol and a lowering in LDL
cholesterol and thereby total cholesterol is beneficial (Bush &
Miller, 1987; Bush & Barratt-Connor, 1985). We are there-
fore undertaking more extensive lipid studies to answer these
questions.
Changes in clotting factors with a lowering of the
fibrinogen/anti-thrombin 3 ratio may indicate a decreased
risk of thrombosis, especially if this is further enhanced by a
significant reduction in serum cholesterol. This may account
for an apparent decrease in non-cancer deaths in two major
adjuvant trials (Scottish Trial Report, 1987; Nato Report,
1980).
Sequential pelvic ultrasound examination in a small sub-
group of women failed to detect a significant effect of
tamoxifen on the ovaries or uterus. At this stage it would
appear that any possible increased risk of ovarian or uterine
cancer is outweighed by a potential reduced risk of cardio-
vascular disease. It is possible that a long-term, unexpected
and serious toxicity of tamoxifen may be identified in the
future, but at this stage it would seem that this is small
compared with the probability of developing breast cancer in
these high risk women. It is anticipated that regular breast,
ovarian, uterine, lipid and clotting screening, together with a
possible reduction in cardiovascular deaths, would more
than outweigh any potential unknown risks.
The results from this feasibility trial indicate that it would
be possible to accrue sufficient high risk women into a
national programme. This would be assisted by identification
of high risk eligible women within the national screening
programme. Accrual of 5,000 women with at least two first
degrees female relatives could probably be achieved within 5
years. Using tamoxifen or placebo, adequate compliance
could be maintained in order to detect a 25% prevention
effect at 10-15 years.
Problems of work load and cost are likely to be signifi-
cant. The cost of tamoxifen and placebo for the feasibility
trial is approximately thirty pounds per woman, per year of
medication. The cost of active screening of 5,000 women,
together with the added extra supervision required for
medication and toxicity assessment, would need to be con-
sidered within a national programme of screening and
prevention.
In conclusion, these preliminary results indicate that
tamoxifen, a proven anti-proliferative agent for endocrine
sensitive breast cancer, is, for the most part, not anti-
oestrogenic in other tissues of the body. This selective
activity, with possible long-term benefits for bone and
vascular disease, together with its low acute toxicity, makes
it an ideal agent for a trial of endocrine prevention of breast
cancer.
Further progress on the developments of a national multi-
centre trial will now depend on extended ethical approval
and the.-upport of such bodies as the Breast Cancer Trials
Co-ordinating Sub-committee and the Cancer Research
Campaign, or other national cancer research bodies.
We thank Farmitalia Carlo Erba for the supply of tamoxifen and
placebo at cost. Without their help this feasibility trial would not
have been possible.
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